DeNovaMed we specializes in developing groundbreaking antibiotics to combat the toughest bacterial infections and diabetic foot ulcers. Our expertise in microbiology and drug design propels us beyond traditional treatments, delivering novel therapies that promise a healthier future.

At DeNovaMed, innovation is the heart of our operations. Our state-of-the-art computer-aided drug design capabilities have yielded multiple classes of antibacterial compounds. These are not only drug-like in their efficacy but are distinctively structured to deter the development of future resistance.

Our preclinical candidate, DNM0547, is a testament to our commitment to underappreciated medical needs. This compound shows great potential as a topical treatment for DFU—a complication of diabetes that is much more common than most people think: 35 - 50 million DFUs/yr globally! Meanwhile, DNM0904, an ACP synthase (AcpS) inhibitor with systemic administration potential, is being tested widely to establish its utility in a variety of infectious diseases, including against multi-drug-resistant Gram-positive infections.

DeNovaMed

Org chart

Teams

Offices

DeNovaMed

Org chart

Teams

Offices

Related companies